11/02/2019 13:01:50

Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

PRESS RELEASE

Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI®. IMFINZI® (durvalumab) is a human monoclonal antibody that blocks the immune checkpoint protein programmed death-ligand (PD-L1). Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study, which is planned to start during 2019.

"We are very pleased with NeoTX's progress in the ANYARA project. The collaboration with AstraZeneca validates the project and is an important step towards start of the clinical study" says Helén Tuvesson, CEO, Active Biotech AB.

See also www.neotx.com for NeoTX's communication related to this information.

ABOUT ANYARA

ANYARA (Naptumumab, Naptumomab estafenatox,) is a tumor targeting immunotherapy that enhances the ability of the immune system to recognize and kill the tumor. ANYARA induces the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells. Preclinical data demonstrate that ANYARA has synergistic effect with checkpoint inhibitors in various tumor models.

Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer.

About NeoTX

NeoTX Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies.

Lund February 11 2019

Helèn Tuvesson

President & CEO

For further information, please contact:

Helén Tuvesson, CEO

Tel +46 46 19 21 56

Hans Kolam, CFO

Tel +46 46 19 20 44

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above,

at 14.00

p.m. CET on February 11, 2019.

Attachment

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Jul
 
Kan vi tåle en fredagsjoke? (og det er ikke Fingerprint Cards jeg tænker på :-) ) En blind mand går ..
31
11 Jul
VELO
Lånt fra skribent i FB gruppen “Veloxis Investor” “Hovedorganisationen for transplantationer i US..
26
12 Jul
 
Man hører det igen og igen. Donald Trump er ubegavet, dum, idiot - derudover racist, nazist - en opp..
25
10 Jul
GEN
I kurs 1500 var der også taget meget forskud på glæderne - og så har der været et par setbacks tilli..
18
12 Jul
PNDORA
Har lige været i Frankrig hvor jeg kiggede forbi en butik hvor jeg konstaterede at der var godt med ..
16
12 Jul
 
Han er den største psykopat, der nogen sinde har siddet ved magten, og han er DYBT ustabil og højst ..
15
11 Jul
DANSKE
Helt enig - desværre.   Danske Bank har i den grad været åben og informativ inden for rammerne af hv..
15
12 Jul
BAVA
Dejligt at se den er begyndt at stige - indenfor 2 1/2 mdr kommer der til at ske rigtig meget:   Ko..
12
12 Jul
 
Det eneste konkrete Tumpen har budt på er en ufinansieret skattereform. Det billigste trick i verden..
12
12 Jul
VELO
Den dér bemærkning kan du sgu' ikke være bekendt.  Synes lige du bør orientere dig bedre dig ved at ..
12

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SolarWinds New APAC Research Shows Insider Threats Rank as Top Cybersecurity Threat Concern
2
ROSEN, A TOP RANKED LAW FIRM, Reminds RCI Hospitality Holdings, Inc. Investors of July 22nd Deadline in Securities Class Action – RICK
3
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
4
ROSEN, A TOP RANKED LAW FIRM, Reminds Community Health Systems, Inc. Investors of Important July 29th Deadline in the Securities Class Action– CYH
5
Black Creek Group Industrial Real Estate Investment Platform to be acquired by Prologis for $3.99 Billion

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2019 09:59:28
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB7 - 2019-07-16 10:59:28 - 2019-07-16 09:59:28 - 1000 - Website: OKAY